Requiring covered entities to provide detailed annual reporting on how 340B revenue is used to ensure direct savings for patients, providing a more transparent link between program savings and ...

Finally, the drugmakers outlined several billion dollars in discounted drugs. Over a roughly six-year period, Eli Lilly outlined $7.5 billion in sales at 340B rates that would have reached $16.9 ...

Becerra (2022) sent shockwaves through the 340B drug pricing program when it ... must meet certain statutory processes that support transparent and non-discriminatory reimbursement practices.

An HHS spokesperson said the agency was reviewing it. The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that serve low-income ...

On the 340B side, our research has identified that ... their business practices are hurting patients. They’re not transparent, and these middlemen are keeping about half of what we call ...